gls-5300
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02670187)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Middle East respiratory syndrome-related coronavirusImmunity, active
Middle East respiratory syndrome-related coronavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gls-5300
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03721718 | Phase 1/Phase 2 (Phase 2) | Aug 28, 2018 | GeneOne Life Science, Inovio Pharmaceuticals, International Vaccine Institute |
| NCT02670187 | Phase 1 | Jan 1, 2016 | GeneOne Life Science, Inovio Pharmaceuticals, United States Army |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GeneOne Life Science | For profit | 2 | 2 | 2 | 2016 |
| Inovio Pharmaceuticals | For profit | 2 | 0 | 2 | 2016 |
| International Vaccine Institute | Academic/Hospital | 1 | 0 | 1 | 2018 |
| United States Army | Government | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1